Clinical Scorecard: Impact of PSA Levels During Salvage Radiotherapy on Metastasis-Free Survival After Radical Prostatectomy

At a Glance

Key Highlights

• Early sRT initiation at PSA < 0.5 ng/ml is associated with improved metastasis-free survival compared to sRT at PSA ≥ 0.5 ng/ml.
• High-risk patients (pT3–4, Gleason 8–10, pN1) particularly benefit from early sRT initiation.
• No specific PSA threshold for sRT initiation is currently recommended by EAU guidelines, but emerging data support initiating sRT at PSA < 0.25 ng/ml.

Guideline-Based Recommendations

Diagnosis

• Biochemical recurrence defined as two consecutive PSA rises or PSA ≥ 0.2 ng/ml after radical prostatectomy.
• Exclude patients with metastatic disease at diagnosis or prior to surgery.

Management

• Administer salvage radiotherapy to the prostatic bed (+/- pelvic lymph nodes) after biochemical recurrence without PSA persistence, at least six months post-prostatectomy.
• Consider concomitant androgen deprivation therapy (ADT) based on physician discretion.
• Adjuvant radiotherapy recommended for patients with high-risk pathological features to reduce recurrence risk.

Monitoring & Follow-up

• Monitor PSA levels regularly to detect biochemical recurrence.
• Use metastasis-free survival as a key oncological outcome measure.
• Apply Kaplan-Meier and Cox regression analyses to evaluate treatment efficacy.

Risks

• Potential side effects and toxicity from radiotherapy may lead some patients to refuse adjuvant treatment.
• Delayed sRT initiation at higher PSA levels may reduce oncological outcomes.

Patient & Prescribing Data

190 prostate cancer patients treated with radical prostatectomy followed by salvage radiotherapy for biochemical recurrence.

69% received early sRT at PSA < 0.5 ng/ml with median PSA 0.24 ng/ml; early sRT patients were younger and had slightly lower tumor infiltration in biopsy cores.

Clinical Best Practices

• Initiate salvage radiotherapy as early as possible after biochemical recurrence, ideally at PSA < 0.5 ng/ml, to improve metastasis-free survival.
• Assess patient risk factors including Gleason score, pathological T- and N-stage, and surgical margins to guide timing of sRT.
• Conduct multidisciplinary tumor board discussions to individualize treatment decisions.
• Follow EAU/ESTRO guidelines for radiation dosing and delivery techniques such as intensity-modulated and image-guided radiotherapy.
• Consider concomitant ADT based on clinical judgment.

References

• European Urology Association (EAU) Guidelines on Prostate Cancer
• Tilki et al. 2023 Study on Salvage Radiotherapy and PSA Thresholds
• University Cancer Center Frankfurt (UCT) Database Study